Efficacy and common side effects of crizotinib/Xalkori

Crizotinib/Crizotinib As the first generationALK inhibitor, it is a milestone in the field of molecular targeted therapy. Its mechanism of action is mainly by selectively inhibiting receptor tyrosine kinase signaling pathways such as ALK, ROS1, and MET, thereby blocking the proliferation and migration of tumor cells and inducing apoptosis. For patients with metastatic non-small cell lung cancer (NSCLC) who are positive for ALK or ROS1 rearrangement, crizotinib has shown significant clinical benefit and can effectively reduce tumor volume and extend progression-free survival. In recent years, the expansion of indications has extended its application scope from lung cancer to lymphoma and inflammatory myofibroblastoma, further demonstrating the value of targeted drugs in medicine.

In real-world applications, the advantage of crizotinib lies not only in its significant antitumor activity but also in its ease of oral administration. Patients can take it long-term in a home environment, improving compliance and quality of life. In particular, the implementation of medical insurance reimbursement has lowered the threshold for medication, allowing more patients to benefit from this innovative therapy. Compared with traditional chemotherapy, crizotinib has better overall tolerability, but there are still some common side effects that require attention.

In terms of adverse reactions, the most common include gastrointestinal symptoms, such as nausea, vomiting, diarrhea and loss of appetite. In addition, some patients may experience visual abnormalities, such as transient blurred vision or changes in light perception, due to the drug's effect on visual signal transmission. Elevated liver function indicators are also seen in some patients, and regular liver function monitoring is required. Fatigue and mild edema are also common, while cardiac adverse reactions are mainly manifested as bradycardia or QT interval prolongation. Electrocardiogram follow-up is performed during treatment.

Reference materials:https://go.drugbank.com/drugs/DB08865